Nevertheless, the lack of an identified disease driver does not preclude patients with C3G from participating in clinical trials of targeted complement inhibitors, and current Kidney Disease: Improving Global Outcomes guidelines recommend that patients with moderate-to-severe C3G who fail to respond to MMF plus glucocorticoids and an anti-C5 antibody be considered for a clinical trial, where available.3 This evidence concerns the gene C5 and kidney disorder.